Severe Asthma Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest Drug Approvals, Emerging Drugs, and Growth Prospects | GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, GenenTech, Boehringer Ingelhe

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Severe Asthma pipeline constitutes key companies continuously working towards developing Severe Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Severe Asthma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Severe Asthma Market.

The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Severe Asthma Pipeline Report: https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Severe Asthma treatment therapies with a considerable amount of success over the years.
• Severe Asthma companies working in the treatment market are Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others, are developing therapies for the Severe Asthma treatment
• Emerging Severe Asthma therapies in the different phases of clinical trials are- LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others are expected to have a significant impact on the Severe Asthma market in the coming years.
• In March 2021, A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-center study of the effectiveness and safety of GSK3511294 adjuvant therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype was started by GlaxoSmithKline
• In January 2021, A 52-week, randomised, double-blind, double-dumy, parallel group, multi-centre, non-inferiority study comparing GSK3511294 to mepolizumab or benralizumab to assess exacerbation rate, additional measures of asthma control, and safety in adult and adolescent participants with severe asthma who have an eosinophilic phenotype was started by GlaxoSmithKline.
• As part of its comprehensive Phase III clinical programme examining the effectiveness and safety of oral dexpramipexole in treating severe eosinophilic asthma, Areteia Therapeutics today reported that the first patients have been dosed in both the EXHALE-2 and EXHALE-4 trials. The complete Phase III development programme will consist of three clinical investigations in total.
• In June 2023, For the treatment of severe asthma, bronchial thermoplasty matches biologics

Severe Asthma Overview
The chronic lung disease known as asthma causes the airways to become inflamed and hyperactive. Asthma has a wide range of signs and symptoms that can be brought on by breathing in environmental allergens including pollen, dust, animal dander, mould, or other irritants.

Get a Free Sample PDF Report to know more about Severe Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Severe Asthma Drugs Under Different Phases of Clinical Development Include:
• LNR 125.38: Lanier Biotherapeutics
• BAT2606: Bio-Thera Solutions
• KN-002: Kinaset Therapeutics
• CM326: CSPC ZhongQi Pharmaceutical Technology
• FB 704A: Oneness Biotech Co., Ltd.
• TQC2731: Chia Tai Tianqing Pharmaceutical Group
• Masitinib: AB Science
• GSK3511294: GlaxoSmithKline

Severe Asthma Pipeline Therapeutics Assessment
• Severe Asthma Assessment by Product Type
• Severe Asthma By Stage and Product Type
• Severe Asthma Assessment by Route of Administration
• Severe Asthma By Stage and Route of Administration
• Severe Asthma Assessment by Molecule Type
• Severe Asthma by Stage and Molecule Type

DelveInsight's Severe Asthma Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Severe Asthma product details are provided in the report. Download the Severe Asthma pipeline report to learn more about the emerging Severe Asthma therapies at:
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Severe Asthma Therapeutics Market include:
Key companies developing therapies for Severe Asthma are - GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, GenenTech, Boehringer Ingelheim Pharmaceuticals, Amgen, Pfizer, AB Science, Teva Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Pieris Pharma, Novartis, Theravance Biopharma, and others.

Severe Asthma Pipeline Analysis:
The Severe Asthma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Severe Asthma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Asthma Treatment.
• Severe Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Severe Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Severe Asthma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Severe Asthma drugs and therapies-
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Severe Asthma Pipeline Market Drivers
• Increase in the prevalence of Severe Asthma, development of new and innovative treatment options for severe asthma are some of the important factors that are fueling the Severe Asthma Market.

Severe Asthma Pipeline Market Barriers
• However, high cost of asthma medications, poor adherence to treatment, limited efficacy of existing treatments and other factors are creating obstacles in the Severe Asthma Market growth.

Scope of Severe Asthma Pipeline Drug Insight
• Coverage: Global
• Key Severe Asthma Companies: Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others
• Key Severe Asthma Therapies: LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others
• Severe Asthma Therapeutic Assessment: Severe Asthma current marketed and Severe Asthma emerging therapies
• Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers

Request for Sample PDF Report for Severe Asthma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/severe-asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Severe Asthma Report Introduction
2 Severe Asthma Executive Summary
3 Severe Asthma Overview
4 Severe Asthma- Analytical Perspective In-depth Commercial Assessment
5 Severe Asthma Pipeline Therapeutics
6 Severe Asthma Late Stage Products (Phase II/III)
7 Severe Asthma Mid Stage Products (Phase II)
8 Severe Asthma Early Stage Products (Phase I)
9 Severe Asthma Preclinical Stage Products
10 Severe Asthma Therapeutics Assessment
11 Severe Asthma Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Severe Asthma Key Companies
14 Severe Asthma Key Products
15 Severe Asthma Unmet Needs
16 Severe Asthma Market Drivers and Barriers
17 Severe Asthma Future Perspectives and Conclusion
18 Severe Asthma Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:
Severe Asthma Market https://www.delveinsight.com/report-store/severe-asthma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Severe Asthma-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Severe Asthma Epidemiology
https://www.delveinsight.com/report-store/severe-asthma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Severe Asthma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.